020/p = 0.136), but the proportions of patients experiencing ≥1 drug-related TEAE APR-246 manufacturer of any grade were similar (<70/≥65/≥70): (PCb, 79.8 %/88.6 %/82.4 %; DCb, 90.6 %/87.9 %/90.0 %; p = 0.056/p = 1.000/p = 0.644). Discontinuations due to possibly drug-related serious AEs occurred in two ≥65-year-old patients in each arm (pemetrexed + carboplatin: 1 anemia and 1 decreased platelet count; docetaxel + carboplatin: 2 febrile neutropenia) and in one ≥70-year-old patient in each arm (pemetrexed + carboplatin: anemia; docetaxel + carboplatin: febrile neutropenia). Notably, there were no on-therapy deaths in either treatment arm in elderly patients, patients aged <70 years, or the Q-ITT population. In patients aged ≥65 years, there were
significantly lower incidences of all-grade drug-related neutropenia, leukopenia, febrile neutropenia, alopecia, and diarrhea in the pemetrexed + carboplatin arm than in the docetaxel + carboplatin
arm (Table 3). Docetaxel + carboplatin-treated patients aged ≥65 years may be more likely to suffer febrile CP673451 in vitro neutropenia than the docetaxel + carboplatin-treated Q-ITT population. Additionally, in patients aged ≥65 years, the incidences of grade 3 or 4 neutropenia, leukopenia, and febrile neutropenia were significantly lower in the pemetrexed + carboplatin arm. Table 3 Frequency of drug-related treatment-emergent adverse events (all grades occurring in ≥5 % of the whole GSK2126458 solubility dmso study population and clinically important grade 3–4)a,b Q-ITT population <70-year age group ≥65-year age group ≥70-year age group Pemetrexed + carboplatin, N = 106 Docetaxel + carboplatin, N = 105 p value Pemetrexed + carboplatin, N = 89 Docetaxel + carboplatin, N = 85 p value Pemetrexed + carboplatin, N = 35 Docetaxel + carboplatin, N = 33 p value Pemetrexed + carboplatin, N = 17 Docetaxel + carboplatin, N = 20 p value Hematological events [n (%)] Neutropenia 42 (39.6) 76 (72.4) <0.001 34 (38.2) 59 (69.4) <0.001 16 (45.7) 26 (78.8) 0.006 8 (47.1) 17 (85.0) 0.032 Grade 3–4 neutropeniac 35 (33.0) 68 (64.8) <0.001 27 (30.3)
52 (61.2) <0.001 14 (40.0) 25 (75.8) 0.004 8 (47.1) 16 (80.0) 0.047 Leukopenia 32 (30.2) 56 (53.3) <0.001 28 (31.5) Temsirolimus price 42 (49.4) 0.020 10 (28.6) 20 (60.6) 0.014 4 (23.5) 14 (70.0) 0.008 Grade 3–4 leukopeniac 17 (16.0) 42 (40.0) <0.001 14 (15.7) 30 (35.3) 0.005 7 (20.0) 18 (54.5) 0.005 3 (17.6) 12 (60.0) 0.018 Anemia 33 (31.1) 16 (15.2) 0.009 29 (32.6) 11 (12.9) 0.002 9 (25.7) 6 (18.2) 0.563 4 (23.5) 5 (25.0) 1.000 Grade 3–4 anemiac 13 (12.3) 2 (1.9) 0.006 10 (11.2) 1 (1.2) 0.010 4 (11.4) 1 (3.0) 0.357 3 (17.6) 1 (5.0) 0.315 Lymphopenia 4 (3.8) 17 (16.2) 0.003 4 (4.5) 13 (15.3) 0.021 1 (2.9) 6 (18.2) 0.051 0 (0.0) 4 (20.0) 0.109 Thrombocytopenia 15 (14.2) 6 (5.7) 0.064 13 (14.6) 5 (5.9) 0.081 5 (14.3) 3 (9.1) 0.710 2 (11.8) 1 (5.0) 0.584 Grade 3–4 thrombocytopeniac 10 (9.4) 3 (2.9) 0.082 9 (10.1) 3 (3.5) 0.133 3 (8.6) 1 (3.0) 0.614 1 (5.9) 0 (0.0) 0.459 Febrile neutropenia 0 (0.0) 9 (8.6) 0.002 0 (0.0) 6 (7.1) 0.012 0 (0.0) 5 (15.2) 0.